古塞奇尤单抗停药后疗效与血清IL-23调控的IL-17和IL-22抑制相关:VOYAGE 2研究
VOYAGE 2研究第28周达到PASI 90的银屑病患者随机分为停药组(n=182)和维持组(n=193)。维持组疗效持续至第72周,停药组疗效下降(PASI 90:86.0% vs 11.5%)。停药后20周再治疗,80.4%停药患者恢复PASI 90。停药后维持应答与IL-17A、IL-17F和IL-22抑制相关。
要点
- 古塞奇尤单抗停药后多数患者失去临床应答,再治疗可恢复。
- 停药后维持应答与血清IL-17A、IL-17F和IL-22抑制相关。
- 细胞因子升高滞后于PASI评分升高,预测复发价值有限。
核心结论
- 古塞奇尤单抗停药后多数患者失去临床应答,再治疗可恢复应答。
- 停药后维持应答与IL-17A、IL-17F和IL-22的抑制相关。
- IL-23信号血清细胞因子升高与疾病复发相关,支持IL-23在Th17、Th22及相关CD8+ T细胞亚群扩增和维持中的作用。
研究设计与样本
- VOYAGE 2研究:第28周达到PASI 90的患者再随机分为停药组(接受安慰剂,n=182)或维持组(n=193)。
- 停药组在失去≥50%第28周PASI改善或至第72周时重新开始古塞奇尤单抗治疗。
- 评估停药后与银屑病复发相关的细胞因子(血清IL-17A、IL-17F、IL-22和IL-23)变化。
主要发现
- 维持组疗效持续至第72周,停药组疗效下降(PASI 90:86.0% vs 11.5%)。
- 停药后20周再治疗,80.4%的停药患者达到PASI 90应答(相对于基线)。
- 停药后维持应答与IL-17A、IL-17F和IL-22的抑制相关。
- 细胞因子水平升高对银屑病复发的预测能力较差,因其升高滞后于PASI评分升高。
临床怎么用
- 古塞奇尤单抗治疗达到PASI 90后停药可能导致多数患者失去应答,再治疗可恢复疗效。
- 监测血清IL-17A、IL-17F和IL-22可能有助于理解停药后应答维持,但不建议用于预测复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guselkumab selectively inhibits IL-23 and in psoriasis, produces high clinical responses, including durable maintenance after treatment withdrawal in some patients. The relationships between IL-23 blockade, serum markers downstream of IL-23 signaling, and withdrawal were explored with guselkumab in VOYAGE 2. METHODS: At week 28, patients with ≥90% Psoriasis Area and Severity Index improvement from baseline (PASI 90) were rerandomized to withdrawal and received placebo (n = 182), or maintenance therapy (n = 193). The guselkumab withdrawal group reinitiated guselkumab upon loss of ≥50% of week- 28 PASI improvement or by week 72. Cytokine changes associated with psoriasis recurrence (serum IL-17A, IL-17F, IL-22, and IL-23) after withdrawal were evaluated. RESULTS: Efficacy in the guselkumab maintenance group was sustained through week 72, whereas efficacy diminished in the guselkumab withdrawal group (PASI 90, 86.0% vs. 11.5%). After 20 weeks of retreatment, 80.4% of guselkumab withdrawal patients achieved PASI 90 responses versus baseline. Maintenance of response after withdrawal was associated with suppression of IL-17A, IL-17F, and IL-22. Increases in cytokine levels had poor predictive power for psoriasis reoccurrence as these increases lagged behind increases in PASI scores. CONCLUSION: Upon guselkumab withdrawal, most patients lost clinical response and regained responses with retreatment. Correlation of IL-23 signaling serum cytokines increased with disease recurrence, supporting the role of IL-23 in expansion and maintenance of CD4+ T helper type 17, T helper type 22, and related CD8+ T-cell subsets producing IL-17A, IL-17F, and IL-22.
引用
- Gordon KB, Armstrong AW, Foley P, et al. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019. PMID: 31207232. doi:10.1016/j.jid.2019.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。